KRTL Biotech Inc. Introduces Expanded Pharmaceutical Portfolio Following Strategic Acquisition

KRTL Holding Group, Inc. (OTC: KRTL) (“KRTL Holding” or the “Company”) today announced that its majority owned subsidiary, KRTL Biotech, Inc. (“KRTL Biotech”), now holds exclusive rights to a robust pharmaceutical product catalog following the recently completed merger of Industria Químico Farmacéutica SIGMA Corp SRL. agreement.

This integration marks a significant expansion of KRTL Biotech’s capabilities across the pharmaceutical value chain, including formulation, packaging, and distribution of essential medications spanning more than a dozen therapeutic areas.

“This catalog reflects decades of medical advancement and our dedication to delivering quality medicines throughout Bolivia and beyond,” said Patricia Wilstermann, CEO of SIGMA. “We are honored to see our work reach new markets through this partnership and are confident in the value it brings to both our communities and KRTL Biotech’s global vision.”

“With this merger, KRTL Biotech now has access to a comprehensive pharmaceutical portfolio produced in accordance with national GMP standards and backed by decades of successful market presence in Latin America,” said Dan Bishop, CEO of KRTL Biotech Inc. “These assets position KRTL Biotech to enter new markets and align with future U.S. regulatory initiatives.”

Product Portfolio Overview

The acquired catalog includes over 150 registered pharmaceutical products, offering a strategically balanced mix of high-demand, essential therapies and specialized health solutions. This portfolio not only reflects regional healthcare priorities but also introduces a foundation of GMP-certified products that can be adapted for broader international commercialization. It spans the following categories:

• Antibiotics and Antivirals

• Digestive and Gastrointestinal Treatments

• Cardiological and Urological Therapies

• Analgesics and Anti-Inflammatories

• Dermatological and Ophthalmological Formulations

• Cognitive Enhancers and Vitamin Supplements

• Biosecurity Products and Dental Health Solutions

• Nutraceuticals and Functional Health Products

This broad range of products—including nutraceuticals, antibiotics, cardiovascular treatments, and pediatric formulations—reflects KRTL Biotech’s deep commitment to addressing both immediate public health needs and emerging healthcare trends across diverse markets. These offerings are strategically aligned with growing global demand for preventive care, accessible treatments, and tailored therapies across multiple age groups and conditions. Some of these categories are also the focus of government-supported initiatives in Bolivia aimed at improving long-term wellness and preventive care. KRTL Biotech will continue to release more detailed announcements highlighting specific product areas, manufacturing initiatives, and regional strategies in both Latin America and the United States.

Dosage forms include tablets, capsules, syrups, injectables, emulsions, and topical agents, manufactured for both pediatric and adult populations.

Strategic Importance of the Product Catalog

This extensive catalog introduces a diverse range of high-demand pharmaceutical products, many of which align with current public health needs and market gaps in the United States. The company is now positioned to evaluate strategic import opportunities and supply select medications across therapeutic areas where accessibility, affordability, and reliability are in high demand.

Flagship products from the catalog include those already proven in Latin American markets and others prioritized for near-term regulatory evaluation in the United States. These selections reflect both commercial readiness and strategic alignment with KRTL Biotech's expansion objectives:

• Broad-spectrum antibiotics and antivirals

• Pediatric formulations in palatable liquid and chewable forms

• Cardiovascular treatments with standardized dosages

• High-demand OTC medications such as analgesics and antihistamines

• Multivitamin supplements tailored for prenatal and geriatric populations

These products are manufactured under stringent GMP conditions, providing a compliant foundation for future regulatory alignment. KRTL Biotech is committed to bridging global pharmaceutical quality with U.S. healthcare needs through responsible sourcing, scalable logistics, and forward-looking distribution strategies.

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.

About Industria Químico Farmacéutica Sigma Corp. S.R.L.

SIGMA is a Bolivian pharmaceutical manufacturer with a long-standing history of quality production, regulatory compliance, and supply chain reliability. The company serves domestic and regional markets through its well-established operations.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.